Meritz Securities emerging as major investor in biotech industry The brokerage house invests $42 mil in three biotech firms in three months
Translated by Kim So-in 공개 2022-02-11 08:16:06
이 기사는 2022년 02월 11일 08:04 thebell 에 표출된 기사입니다.
Meritz Securities is emerging as a big player in the biotech industry, making investments worth billions of won over the last three months.Meritz Securities has made principal investments totaling 50 billion won ($42 million) in three biotech firms - Huinno, ImmuneOncia Therapeutics, and Therabest - from October to December 2021, more than 15 billion won in each firm, according to industry sources said.
Huinno is a healthcare startup developing wearable solutions. Yuhan Corp became the second largest shareholder of the company two years ago. Meritz Securities made a pre-initial public offering (pre-IPO) investment in Huinno in December 2021, valuing the company at 250 billion won. The valuation grew 10 times since Yuhan made its investment. SL Investment, KTB Network, Korea Development Bank, A Ventures, and A1 Ventures also participated in the pre-IPO funding.
ImmuneOncia is a joint venture formed by Yuhan and Nasdaq-listed Sorrento Therapeutics. The company raised 24.5 billion won in a pre-IPO placement in January, which valued the company at about 250 billion won. Meritz Securities, Yuhan, the largest shareholder of ImmuneOncia, Premier Partners, K2 Investment Partners, Shinvestor & Partners, BNH Investment, E& Investment, and Hanyang Securities participated in the funding round.
Therabest develops induced pluripotent stem cell (iPSC)-derived NK cell therapy. Yuhan is also the largest shareholder of the company. Meritz Securities joined a Series C funding round in November 2011, valuing Therabest at 180 billion won. Other investors included DS Asset, DA Value Investment, and Cloud IB Investment.
Meritz Securities’ investments in the biotech companies are led by Kim Jae-kyo, vice president of the brokerage firm’s investment & development division. Kim served as director and head of global strategy division at Yuhan, where he handled mergers and acquisitions and investments in biotech firms at home and abroad.
Meritz Securities plans to make investments with an emphasis on development. It will consider ways to maximize a company's technology and expand its valuation, instead of simply injecting capital.
“We aim to make investments that would open the way for biotech firms with technology to enhance their competitiveness,” said an official at Meritz Securities. “We plan to create a virtuous cycle that promotes trust in K-Bio through investments focusing on development.”(Reporting by Eun-jin Choi)
< 저작권자 ⓒ 자본시장 미디어 'thebell', 무단 전재, 재배포 및 AI학습 이용 금지 >
관련기사
best clicks
최신뉴스 in 전체기사
-
- 우리금융 "롯데손보 M&A, 과도한 가격 부담 안한다"
- 신한캐피탈, 지속성장 포트폴리오 리밸런싱 체계 강화
- 하나금융, ELS 악재에도 실적 선방…확고한 수익 기반
- 하나금융, 자본비율 하락에도 주주환원 강화 의지
- 국민연금, '역대 최대 1.5조' 출자사업 닻 올렸다
- [도전 직면한 하이브 멀티레이블]하이브, 강한 자율성 보장 '양날의 검' 됐나
- [퍼포먼스&스톡]꺾여버린 기세에…포스코홀딩스, '자사주 소각' 카드 재소환
- [퍼포먼스&스톡]LG엔솔 예견된 실적·주가 하락, 비용 절감 '집중'
- [퍼포먼스&스톡]포스코인터, 컨센서스 웃돌았지만 주가는 '주춤'
- 신한금융, ‘리딩금융’ 재탈환에 주주환원 강화 자신감